0001209191-23-046513.txt : 20230818 0001209191-23-046513.hdr.sgml : 20230818 20230818160013 ACCESSION NUMBER: 0001209191-23-046513 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230808 FILED AS OF DATE: 20230818 DATE AS OF CHANGE: 20230818 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dunn Edmund CENTRAL INDEX KEY: 0001989401 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 231185790 MAIL ADDRESS: STREET 1: MONTE ROSA THERAPEUTICS, INC. STREET 2: 321 HARRISON AVENUE, SUITE 900 CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE STREET 2: SUITE 900 CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE STREET 2: SUITE 900 CITY: BOSTON STATE: MA ZIP: 02118 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-08-08 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001989401 Dunn Edmund MONTE ROSA THERAPEUTICS, INC. 321 HARRISON AVENUE, SUITE 900 BOSTON MA 02210 0 1 0 0 Principal Accounting Officer Common Stock 16761 D Stock Option (Right to Buy) 6.14 2031-04-11 Common Stock 14515 D Stock Option (Right to Buy) 13.41 2032-02-29 Common Stock 25700 D Stock Option (Right to Buy) 7.78 2033-01-02 Common Stock 35900 D Consists of restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of this option vested and became exercisable on March 17, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. 25% of this option vested and became exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Exhibit 24 - Power of Attorney /s/ Phil Nickson, Attorney-in-Fact 2023-08-18 EX-24 2 attachment1.htm EX-24 DOCUMENT
                            LIMITED POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints each of Markus Warmuth
and Phil Nickson, signing singly, and with full power of substitution, the
undersigned's true and lawful attorney-in-fact to:

        (1)   execute for and on behalf of the undersigned, in the
undersigned's capacity as officer and/or director of Monte Rosa Therapeutics,
Inc. (the "Company"), from time to time the following U.S. Securities and
Exchange Commission ("SEC") forms: (i) Form ID, including any attached
documents, to effect the assignment of codes to the undersigned to be used in
the transmission of information to the SEC using the EDGAR System; (ii) Form 3,
Initial Statement of Beneficial Ownership of Securities, including any attached
documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of
Securities, including any attached documents; (iv) Form 5, Annual Statement of
Beneficial Ownership of Securities in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended, and the rules thereunder,
including any attached documents; (v) Schedules 13D and 13G; and (vi)
amendments of each thereof, in accordance with the Securities Exchange Act of
1934, as amended, and the rules thereunder, including any attached documents;

        (2)   do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute any
such Form 3, 4 or 5, Schedule 13D or 13G, or any amendment(s) thereto and
timely file such form(s) with the SEC and any securities exchange, national
association or similar authority; and

        (3)   take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorneys-in-fact.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee
of the Company.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of August 8, 2023.

                                   /s/ Edmund Dunn
                                   -------------------------------
                                   Signature


                                   Edmund Dunn
                                   -------------------------------
                                   Print Name